Nahoko Nishimoto

632 total citations
13 papers, 476 citations indexed

About

Nahoko Nishimoto is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Nahoko Nishimoto has authored 13 papers receiving a total of 476 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 4 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Nahoko Nishimoto's work include Acute Myeloid Leukemia Research (7 papers), Hematopoietic Stem Cell Transplantation (3 papers) and Fungal Infections and Studies (2 papers). Nahoko Nishimoto is often cited by papers focused on Acute Myeloid Leukemia Research (7 papers), Hematopoietic Stem Cell Transplantation (3 papers) and Fungal Infections and Studies (2 papers). Nahoko Nishimoto collaborates with scholars based in Japan and United States. Nahoko Nishimoto's co-authors include Mineo Kurokawa, Masahiro Nakagawa, Motoshi Ichikawa, Akihide Yoshimi, Naoko Watanabe‐Okochi, Susumu Goyama, Shunya Arai, Yoichi Imai, Lea Cunningham and Mark Wunderlich and has published in prestigious journals such as Journal of Clinical Investigation, Blood and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Nahoko Nishimoto

13 papers receiving 474 citations

Peers

Countries citing papers authored by Nahoko Nishimoto

Since Specialization

Citations

This map shows the geographic impact of Nahoko Nishimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nahoko Nishimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nahoko Nishimoto more than expected).

Fields of papers citing papers by Nahoko Nishimoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nahoko Nishimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nahoko Nishimoto. The network helps show where Nahoko Nishimoto may publish in the future.

Co-authorship network of co-authors of Nahoko Nishimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Nahoko Nishimoto. A scholar is included among the top collaborators of Nahoko Nishimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nahoko Nishimoto. Nahoko Nishimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Epidemiological study using IgM and IgG antibody titers against SARS-CoV-2 in The University of Tokyo, Japan (UT-CATS) 2021 ·Journal of Infection and Chemotherapy ·Akihisa Mitani, (unknown), (unknown), Yoshifumi Morita, (unknown), Yukiko Inoue, Minako Saito, Takashi Ishii, Mitsuhiro Sunohara, Ryota Takahashi, (unknown), Nahoko Nishimoto, Y. Murano, Sachiko Okazaki, (unknown), Atsushi Yao, (unknown), Makoto Kurano, Yutaka Yatomi, Shintaro Yanagimoto	3
2	Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells 2013 ·Journal of Clinical Investigation ·Susumu Goyama, (unknown), Lea Cunningham, Yue Zhang, (unknown), Nahoko Nishimoto, Masahiro Nakagawa, André Olsson, Mark Wunderlich, Kevin A. Link, Benjamin Mizukawa, H. Leighton Grimes, Mineo Kurokawa, (unknown), Gang Huang, James C. Mulloy	151
3	Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) 2013 ·Bone Marrow Transplantation ·Junji Tanaka, Heiwa Kanamori, Satoshi Nishiwaki, Kazuteru Ohashi, Satoshi Taniguchi, Tetsuya Eto, Hirohisa Nakamae, Kentaro Minagawa, Koichi Miyamura, Hisashi Sakamaki, Y Morishima, Koji Kato, Ritsuro Suzuki, Nahoko Nishimoto, Koji Oba, Nobuo Masauzi	25
4	A role for RUNX1 in hematopoiesis and myeloid leukemia 2013 ·International Journal of Hematology ·Motoshi Ichikawa, Akihide Yoshimi, Masahiro Nakagawa, Nahoko Nishimoto, Naoko Watanabe‐Okochi, Mineo Kurokawa	86
5	Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells 2013 ·Journal of Clinical Investigation ·Susumu Goyama, (unknown), Lea Cunningham, Yue Zhang, (unknown), Nahoko Nishimoto, Masahiro Nakagawa, André Olsson, Mark Wunderlich, Kevin A. Link, Benjamin Mizukawa, (unknown), Mineo Kurokawa, (unknown), Gang Huang, James C. Mulloy	5
6	The first case of blastic plasmacytoid dendritic cell neoplasm with MLL-ENL rearrangement 2011 ·Leukemia Research ·Takashi Toya, Nahoko Nishimoto, Junji Koya, Masahiro Nakagawa, Fumihiko Nakamura, (unknown), Go Yamamoto, Yasuhito Nannya, Motoshi Ichikawa, Mineo Kurokawa	18
7	Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19ARF 2011 ·Blood ·Nahoko Nishimoto, Shunya Arai, Motoshi Ichikawa, Masahiro Nakagawa, Susumu Goyama, Keiki Kumano, Tsuyoshi Takahashi, Yasuhiko Kamikubo, Yoichi Imai, Mineo Kurokawa	28
8	AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors 2011 ·Blood ·Masahiro Nakagawa, Munetake Shimabe, Naoko Watanabe‐Okochi, Shunya Arai, Akihide Yoshimi, Akihito Shinohara, Nahoko Nishimoto, Keisuke Kataoka, Tomohiko Sato, Keiki Kumano, Yasuhito Nannya, Motoshi Ichikawa, Yoichi Imai, Mineo Kurokawa	47
9	T cell acute lymphoblastic leukemia arising from familial platelet disorder 2010 ·International Journal of Hematology ·Nahoko Nishimoto, Yoichi Imai, Koki Ueda, Masahiro Nakagawa, Akihito Shinohara, Motoshi Ichikawa, Yasuhito Nannya, Mineo Kurokawa	33
10	AML1/Runx1 Is a Cytoplasmic Attenuator of NF-Kb Signaling: Implication in Pathogenesis and Targeted Therapy of AML1-Related Leukemia. 2009 ·Blood ·Masahiro Nakagawa, Munetake Shimabe, Nahoko Nishimoto, Naoko Watanabe‐Okochi, Motoshi Ichikawa, Yasuhito Nannya, Yoichi Imai, Mineo Kurokawa	2
11	Decreased incidence of acute graft‐versus‐host disease by continuous infusion of cyclosporine with a higher target blood level 2007 ·American Journal of Hematology ·Kumi Oshima, Yoshinobu Kanda, Hideki Nakasone, Shunya Arai, Nahoko Nishimoto, Hiroyuki Satō, Takuro Watanabe, Noriko Hosoya, Koji Izutsu, Takashi Asai, Akira Hangaishi, Toru Motokura, Shigeru Chiba, Mineo Kurokawa	39
12	Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients 2007 ·Journal of Antimicrobial Chemotherapy ·Kumi Oshima, Yoshinobu Kanda, Yuki Asano‐Mori, Nahoko Nishimoto, Shunya Arai, Sumimasa Nagai, Hiroyuki Satō, Takuro Watanabe, Noriko Hosoya, Koji Izutsu, Takashi Asai, Akira Hangaishi, Toru Motokura, Shigeru Chiba, Mineo Kurokawa	24
13	Late onset of autoimmune hemolytic anemia and pure red cell aplasia after allogeneic hematopoietic stem cell transplantation using in vivo alemtuzumab 2007 ·American Journal of Hematology ·Shinichi Kako, Yoshinobu Kanda, Kumi Oshima, Nahoko Nishimoto, Hiroyuki Satō, Takuro Watanabe, Noriko Hosoya, Toru Motokura, Shigesaburo Miyakoshi, Shuichi Taniguchi, Aki Kamijo, Koki Takahashi, Shigeru Chiba, Mineo Kurokawa	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact